Supported by

Stents, scaffolds and DCB

Find all the latest content on stents and scaffolds published on this website.

Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools, devices and techniques; the role of adjunctive pharmacotherapy; advances in imaging techniques as well as the use of invasive imaging and functional assessment. Find out more…

Filtered By
Stents, scaffolds and DCB

543 results

Putting evidence in clinical practice of managing high-bleeding risk (HBR) patients

06 Oct 2021 – From AICT-AsiaPCR 2021

In this video, Aaron Wong and Paul Ong share their views on the contribution of various stents to the treatment of HBR patients and the value of durable, biodegradable, non-polymer stents in specific cases. They base their discussion on the results of numerous studies on stents using...

Putting evidence in clinical practice of managing HBR patients

Treating complex coronary lesions: right case right time Prevail™ DCB

01 Oct 2021 – From AICT-AsiaPCR 2021

Thanks to this session, find out more about indications for drug-coated balloons, or, on the contrary, learn when not to use it. And through the analysis of two concrete cases, see how DCB can be an important tool to tackle increasingly complex patients and anatomies, especially...

Treating complex coronary lesions: right case right time Prevail™ DCB

Telescope guide extension catheter in complex coronary interventions

01 Oct 2021 – From AICT-AsiaPCR 2021

View the complex case of this 70-year-old male patient with hypertension and diabetes who presented with chest pain and NSTEMI, which shows that, when dealing with challenging calcific disease, guide catheter extensions help improve device delivery.

Telescope guide extension

MASTER DAPT trial: dual antiplatelet therapy after coronary stenting in high bleeding risk patients

01 Oct 2021 – From AICT-AsiaPCR 2021

In this session dedicated to the MASTER DAPT study, considered the largest HBR trial to date, learn about the baseline characteristics, clinical presentation, and procedural characteristics of this large trial carried out across 4 continents, before hearing our speakers' interpretation of its 30-days outcomes.

MASTER DAPT trial: dual antiplatelet therapy after coronary stenting in high bleeding risk patients

Imaging and robotics in the catheterization laboratory of the future

20 Sep 2021

At a time when the prevention of the health of health care personnel is at the forefront, as well as that of the patient, innovations in imaging are arousing increasing interest. Similarly, the integration of new technologies, and in particular the use of artificial intelligence and...

Rafael Beyar

Author

Rafael Beyar
Justin Davies

Author

Justin Davies

Author

Christopher Cook
Prof. Dariusz Dudek

Author

Dariusz Dudek
Paul Cummins

Author

Paul Cummins
Dr. Nico Bruining

Author

Nico Bruining
Imaging and robotics in the catheterization laboratory of the future

Delayed compromise of a “super dominant” RCA and Shock

14 Sep 2021

Coronary obstruction is a known procedural complication of aortic valve replacement. However, delayed presentation few months after surgical AVR is a relatively unusual phenomenon.  We describe a 75 year old woman with surgical AVR who presented with acute coronary syndrome and severe RV failure few months...

Tesfaye A. Telila

Author

Tesfaye A. Telila
Delayed compromise of a “super dominant” RCA and Shock

MASTER-DAPT: “the MASTER of high-bleeding risk trials”

28 Aug 2021

Marco Valgimigli (Lugano, Switzerland) presented the results of the MASTER DAPT trial on Saturday, August 28, in a Hot Line session of the ESC Congress 2021. Luis G. Ortega-Paz provides his PICOT & SWOT analysis of this study.

Luis Ortega-Paz

Author

Luis Ortega-Paz
ESC Congress 2021 - MASTER-DAPT : “the MASTER of high-bleeding risk trials”

MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients - interview with Marco Valgimigli

28 Aug 2021

ESC Congress 2021: Discover the interview given by Marco Valgimigli to Luis G. Ortega-Paz for PCRonline about the MASTER-DAPT trial to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events.

Luis Ortega-Paz

Author

Luis Ortega-Paz
Marco Valgimigli

Author

Marco Valgimigli
ESC Congress 2021 - MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients

Stent expansion indexes to predict clinical outcomes: an IVUS substudy from ADAPT-DES

23 Aug 2021

The purpose of the present investigation was to revisit all stent expansion indexes to identify the best predictor of 2-year percutaneous coronary intervention (PCI) lesion-specific outcome measures (i.e. clinically-driven target lesion revascularization [TLR] or definite stent thrombosis) using the ADAPT-DES IVUS substudy cohort.

Reviewer

Salvatore Brugaletta
Stent expansion indexes to predict clinical outcomes: an IVUS substudy from ADAPT-DES

Two cases of circumflex coronary anomaly arising from RCA: one of them with inferior STEMI and VT

28 Jul 2021

The origin of circumflex from the main RCA has a reported incidence of 0.37 %. Here are two very unusual cases of an anomalous origin of the left circumflex coronary artery from the proximal RCA, one of them with inferior STEMI and VT.

Juan Guzman Olea

Author

Juan Guzman Olea

Author

Gabriel Guzmán Olea

Author

Gonzalo Tolosa Dzul

Author

Rodrigo Manzo Guzmán

Author

Daniel Iván Pérez Vásquez
Suárez Romero Suárez Romero

Author

Elizabeth Suárez Romero

Author

Antonio Fernando Real Ramírez
Two cases of circumflex coronary anomaly arising from RCA: one of them with inferior STEMI and VT